Fig 1: Vemurafenib inhibited mTOR and p70S6K activation in dyW−/− mice. Levels of (A) phosphorylated ERK1/2 (pT202/Y204), (B) phosphorylated STAT3 (pY705), (C) phosphorylated NFκB p65 (pS536), (D) phosphorylated JNK1/2 (pT183/Y185), (E) phosphorylated mTOR (pS2448) and (F) phosphorylated p70S6K (pT389) in protein extracts of gastrocnemius muscle from WT mice, vehicle-treated dyW−/− mice and vemurafenib-treated dyW−/− mice. One-way ANOVA with uncorrected Fisher's LSD test was performed for the data that followed the normal distribution [ERK1/2 (pT202/Y204), mTOR (pS2448) and NFκB p65 (pS536)]. Kruskal–Wallis test was performed for the data that did not follow the normal distribution [STAT3 (pY705), JNK1/2 (pT183/Y185) and p70S6K (pT389)]. All data are represented by statistical significance of mean±s.e.m. (n=10 for all groups). ns, not significant; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.